Afinitor for prostate cancer
Afinitor s is currently in clinical trials for prostate cancer and only preliminary information is available. For example, it is in the phase II study: Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer, NCT00976755. Several studies have been performed and published. A phase II study (Templeton et al., 2011) investigating the activity of everolimus 10mg/daily as first-line treatment found that in 37 enrolled patients,
Read more